Dec 23
|
U.S. Food and Drug Administration issues Complete Response Letter for dasiglucagon in congenital hyperinsulinism for up to three weeks of dosing due to inspection findings at third-party manufacturing facility
|
Dec 22
|
Zealand Pharma submits New Drug Application to the US FDA for glepaglutide in short bowel syndrome
|
Dec 22
|
Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank
|
Dec 7
|
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
|
Dec 7
|
Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants
|
Dec 4
|
Zealand Pharma to highlight obesity pipeline at R&D Event on December 5
|
Nov 30
|
Total number of shares and voting rights in Zealand Pharma at November 30, 2023
|
Nov 30
|
Zealand Pharma appoints Enrique Conterno and Elaine Sullivan as board observers
|
Sep 29
|
Total number of shares and voting rights in Zealand Pharma at September 29, 2023
|